Crohn's disease trials in Brazil

In Brazil 18 Also abroad 422

18 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Botucatu, Campinas, Jaú, Porto Alegre, Ribeirão Preto, Santo André, São José do Rio Preto, São Paulo
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 3Taking people
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Where
Jaú, Porto Alegre, São Paulo
Age
2 years to 17 years
People
100 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07298421 · EU 2025-523318-96-00
Phase 2Taking people
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Where
Aracaju, Botucatu, Brasília, Campinas, Santo André, São Paulo
Age
18 years to 85 years
People
385 worldwide
Run by
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00
Phase 3Taking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Aracaju, Brasília, Campinas, Caxias do Sul, Curitiba, Juiz de Fora, Porto Alegre, Ribeirão Preto, Salvador, Santo André, São Paulo, Vitória, Votuporanga
Age
18 years to 70 years
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
Phase 2Taking people
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Where
Campinas, Caxias do Sul, Curitiba, Marília, São Paulo, Vitória
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00
Phase 2Taking people
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Where
Campinas, Caxias do Sul, Curitiba, Marília, São Paulo, Vitória
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483099
Phase 3Taking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Campinas, Curitiba, Goiânia, Porto Alegre, Vitória, Votuporanga
Age
2 years to 17 years
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Goiânia, Votuporanga
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Belo Horizonte, Botucatu, Brasília, Curitiba, Fortaleza, Jaú, Juiz de Fora, Macaé, Natal, Niterói, Porto Alegre, Recife, Ribeirão Preto, Salvador, Santo André, Santos, São José do Rio Preto, São Paulo, Votuporanga
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Botucatu, Brasília, Curitiba, Jaú, Juiz de Fora, Macaé, Natal, Niterói, Porto Alegre, Ribeirão Preto, Salvador, Santo André, São Paulo, Votuporanga
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Botucatu, Brasília, Campinas, Jaú, Juiz de Fora, Porto Alegre, Ribeirão Preto, Santos, São Paulo
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Aracaju, Jaú, Porto Alegre, São José do Rio Preto, São Paulo, Volta Redonda
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Aracaju, Barretos, Brasília, Campinas, Caxias do Sul, Goiânia, Juiz de Fora, Porto Alegre, Salvador, São José do Rio Preto, São Paulo, Teresina
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
São José do Rio Preto
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Botucatu, Brasília, Campinas, Curitiba, Porto Alegre, Salvador, São Paulo
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Campinas, Curitiba, Goiânia, Porto Alegre, Vitória, Votuporanga
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
Phase 3Taking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Campinas, Curitiba-PR, Goiânia, Porto Alegre, Santos Dumont, Votuporanga
Age
2 years to 17 years
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
Phase 3Taking people
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Where
Botucatu, Curitiba, Jaú, Rio de Janeiro, Santo André, São Paulo
Age
18 years to 65 years
People
396 worldwide
Run by
Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00